AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.22 |
Market Cap | 36.60M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.99 |
PE Ratio (ttm) | -0.62 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.31 |
Volume | 79,207 |
Avg. Volume (20D) | 507,370 |
Open | 1.27 |
Previous Close | 1.26 |
Day's Range | 1.22 - 1.28 |
52-Week Range | 0.87 - 21.55 |
Beta | undefined |
About ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California....
Analyst Forecast
According to 5 analyst ratings, the average rating for ANTX stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 185.71% from the latest price.
2 months ago · businesswire.com
AN2 Therapeutics to Participate at Upcoming Investor ConferencesMENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c...